Liver fat reduction with niacin is influenced by DGAT-2 polymorphisms in hypertriglyceridemic patients

Journal of Lipid Research

Volumn 53, Issue 4, 2012, Pages 802-809

  Hu, Miao ^a   Chu, Winnie Chiu Wing ^a   Yamashita, Shizuya ^b   Yeung, David Ka Wai ^a   Shi, Lin ^a   Wang, Defeng ^a   Masuda, Daisaku ^b   Yang, Yaling ^a   Tomlinson, Brian ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Diacylglycerol acyltransferase 2; Dyslipidemia; Fatty liver; Free fatty acid

Indexed keywords

DIACYLGLYCEROL ACYLTRANSFERASE 2; NICOTINIC ACID; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL;

ADULT; AGED; ALLELE; ARTICLE; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; DGAT 2 GENE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERTRIGLYCERIDEMIA; INTRAABDOMINAL FAT; LIVER; MALE; PRIORITY JOURNAL; SUBCUTANEOUS FAT; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; BODY WEIGHT; DIACYLGLYCEROL O-ACYLTRANSFERASE; FEMALE; GENOTYPING TECHNIQUES; HUMANS; HYPERTRIGLYCERIDEMIA; INTRA-ABDOMINAL FAT; LIVER; MALE; MIDDLE AGED; NIACIN; POLYMORPHISM, GENETIC; SUBCUTANEOUS FAT; TRIGLYCERIDES; YOUNG ADULT;

EID: 84859418039     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P023614     Document Type: Article

References (32)

1. Targher, G., F. Marra, and G. Marchesini. 2008. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia. 51: 1947-1953.
2. Gastaldelli, A., M. Kozakova, K. Hojlund, A. Flyvbjerg, A. Favuzzi, A. Mitrakou, and B. Balkau. 2009. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology. 49: 1537-1544.
3. Cohen, J. C., J. D. Horton, and H. H. Hobbs. 2011. Human fatty liver disease: old questions and new insights. Science. 332: 1519-1523.
4. Donnelly, K. L., C. I. Smith, S. J. Schwarzenberg, J. Jessurun, M. D. Boldt, and E. J. Parks. 2005. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115: 1343-1351. (Pubitemid 40629054)
5. Carlson, L. A. 2005. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J. Intern. Med. 258: 94-114. (Pubitemid 41025967)
6. Gille, A., E. T. Bodor, K. Ahmed, and S. Offermanns. 2008. Nicotinic acid: pharmacological effects and mechanisms of action. Annu. Rev. Pharmacol. Toxicol. 48: 79-106. (Pubitemid 351738150)
7. Carlson, L. A., and L. Oro. 1962. The effect of nicotinic acid on the plasma free fatty acid; demonstration of a metabolic type of sympathicolysis. Acta Med. Scand. 172: 641-645.
8. Vega, G. L., N. B. Cater, S. Meguro, and S. M. Grundy. 2005. Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia. Am. J. Cardiol. 95: 1309-1313. (Pubitemid 40719861)
9. Ganji, S. H., S. Tavintharan, D. Zhu, Y. Xing, V. S. Kamanna, and M. L. Kashyap. 2004. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J. Lipid Res. 45: 1835-1845. (Pubitemid 40990875)
10. Le Bloc'h, J., V. Leray, M. Chetiveaux, B. Freuchet, T. Magot, M. Krempf, P. Nguyen, and K. Ouguerram. 2010. Nicotinic acid decreases apolipoprotein B100-containing lipoprotein levels by reducing hepatic very low density lipoprotein secretion through a possible diacylglycerol acyltransferase 2 inhibition in obese dogs. J. Pharmacol. Exp. Ther. 334: 583-589.
11. Yu, X. X., S. F. Murray, S. K. Pandey, S. L. Booten, D. Bao, X. Z. Song, S. Kelly, S. Chen, R. McKay, B. P. Monia, et al. 2005. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology. 42: 362-371. (Pubitemid 41061089)
12. Fabbrini, E., B. S. Mohammed, K. M. Korenblat, F. Magkos, J. McCrea, B. W. Patterson, and S. Klein. 2010. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 95: 2727-2735.
13. Kantartzis, K., F. Machicao, J. Machann, F. Schick, A. Fritsche, H. U. Haring, and N. Stefan. 2009. The DGAT2 gene is a candidate for the dissociation between fatty liver and insulin resistance in humans. Clin. Sci. (Lond.). 116: 531-537.
14. Browning, J. D., L. S. Szczepaniak, R. Dobbins, P. Nuremberg, J. D. Horton, J. C. Cohen, S. M. Grundy, and H. H. Hobbs. 2004. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 40: 1387-1395. (Pubitemid 39657013)
15. Eggers, H., B. Brendel, A. Duijndam, and G. Herigault. 2011. Dualecho Dixon imaging with flexible choice of echo times. Magn. Reson. Med. 65: 96-107.
16. Friedel, S., K. Reichwald, A. Scherag, H. Brumm, A. K. Wermter, H. R. Fries, K. Koberwitz, M. Wabitsch, T. Meitinger, M. Platzer, et al. 2007. Mutation screen and association studies in the diacylglycerol O-acyltransferase homolog 2 gene (DGAT2), a positional candidate gene for early onset obesity on chromosome 11q13. BMC Genet. 8: 17.
17. Promrat, K., D. E. Kleiner, H. M. Niemeier, E. Jackvony, M. Kearns, J. R. Wands, J. L. Fava, and R. R. Wing. 2010. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 51: 121-129.
18. Linke, A., M. Sonnabend, M. Fasshauer, R. Hollriegel, G. Schuler, J. Niebauer, M. Stumvoll, and M. Bluher. 2009. Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance. Atherosclerosis. 205: 207-213.
19. Monetti, M., M. C. Levin, M. J. Watt, M. P. Sajan, S. Marmor, B. K. Hubbard, R. D. Stevens, J. R. Bain, C. B. Newgard, R. V. Farese, Sr., et al. 2007. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab. 6: 69-78. (Pubitemid 46995777)
20. Wang, Z., T. Yao, and Z. Song. 2010. Involvement and mechanism of DGAT2 upregulation in the pathogenesis of alcoholic fatty liver disease. J. Lipid Res. 51: 3158-3165.
21. Yen, C. L., S. J. Stone, S. Koliwad, C. Harris, and R. V. Farese, Jr. 2008. Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis. J. Lipid Res. 49: 2283-2301.
22. Yin, Q., H. W. Yang, X. L. Han, B. Fan, and B. Liu. 2011. Isolation, mapping, SNP detection and association with backfat traits of the porcine CTNNBL1 and DGAT2 genes. Mol. Biol. Rep. Epub ahead of print. October 14, 2011; doi:.
23. Yamaguchi, K., L. Yang, S. McCall, J. Huang, X. X. Yu, S. K. Pandey, S. Bhanot, B. P. Monia, Y. X. Li, and A. M. Diehl. 2007. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 45: 1366-1374. (Pubitemid 46918320)
24. Oh, Y. T., K. S. Oh, Y. M. Choi, A. Jokiaho, C. Donovan, S. Choi, I. Kang, and J. H. Youn. 2011. Continuous 24-h nicotinic acid infusion in rats causes FFA rebound and insulin resistance by altering gene expression and basal lipolysis in adipose tissue. Am. J. Physiol. Endocrinol. Metab. 300: E1012-E1021.
25. Kang, I., S. W. Kim, and J. H. Youn. 2011. Effects of nicotinic acid on gene expression: potential mechanisms and implications for wanted and unwanted effects of the lipid-lowering drug. J. Clin. Endocrinol. Metab. 96: 3048-3055.
26. Neuschwander-Tetri, B. A. 2010. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. 52: 774-788.
27. Choi, S. S., and A. M. Diehl. 2008. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. Curr. Opin. Lipidol. 19: 295-300. (Pubitemid 351653569)
28. McKenney, J. M., J. D. Proctor, S. Harris, and V. M. Chinchili. 1994. A comparison of the efficacy and toxic effects of sustainedvs immediate-release niacin in hypercholesterolemic patients. JAMA. 271: 672-677.
29. Harris, W. S. 1997. n-3 fatty acids and serum lipoproteins: human studies. Am. J. Clin. Nutr. 65: 1645S-1654S. (Pubitemid 27187958)
30. Wi, J., J. Y. Kim, S. Park, S. M. Kang, Y. Jang, N. Chung, W. H. Shim, S. Y. Cho, and S. H. Lee. 2010. Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein- cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg. Atherosclerosis. 213: 235-240.
31. Sørensen, N. S., P. Marckmann, C. E. Hoy, W. van Duyvenvoorde, and H. M. Princen. 1998. Effect of fish-oil-enriched margarine on plasma lipids, low-density-lipoprotein particle composition, size, and susceptibility to oxidation. Am. J. Clin. Nutr. 68: 235-241. (Pubitemid 28355638)
32. Nestel, P. J. 2000. Fish oil and cardiovascular disease: lipids and arterial function. Am. J. Clin. Nutr. 71: 228S-231S. (Pubitemid 30046121)